- Home
- TWLO vs RVMD Comparison
TWLO vs RVMD Comparison
Compare TWLO & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWLO | RVMD |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 15.2B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TWLO | RVMD |
|---|---|---|
| Price | $108.77 | $95.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 16 |
| Target Price | ★ $144.92 | $102.63 |
| AVG Volume (30 Days) | 2.4M | ★ 5.8M |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $4,896,125,000.00 | N/A |
| Revenue This Year | $14.87 | N/A |
| Revenue Next Year | $8.79 | $740.40 |
| P/E Ratio | $281.71 | ★ N/A |
| Revenue Growth | ★ 12.84 | N/A |
| 52 Week Low | $77.51 | $29.17 |
| 52 Week High | $149.19 | $124.49 |
Technical Indicators
Market Signals| Indicator | TWLO | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 45.20 |
| Support Level | $116.11 | $96.72 |
| Resistance Level | $137.64 | $101.93 |
| Average True Range (ATR) | 5.82 | 3.97 |
| MACD | -1.50 | -3.41 |
| Stochastic Oscillator | 9.61 | 10.28 |
Price Performance
Historical ComparisonAbout TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.